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DOI 10.1016/j.ccr.2010.11.007SUMMARYBasal cell carcinomas (BCCs) are hedgehog-driven tumors that resemble follicular and interfollicular
epidermal basal keratinocytes and hence long have been thought to arise from these cells. However, the
actual cell of origin is unknown. Using cell fate tracking of X-ray induced BCCs in Ptch1+/ mice, we found
their essentially exclusive origin to be keratin 15-expressing stem cells of the follicular bulge. However, condi-
tional loss of p53 not only enhanced BCC carcinogenesis from the bulge but also produced BCCs from the
interfollicular epidermis, at least in part by enhancing Smo expression. This latter finding is consistent with
the lack of visible tumors on ears and tail, sites lacking Smo expression, in Ptch1+/ mice.INTRODUCTION
The cell of origin of most cancers has yet to be established. The
majority of data thus far accumulated favor either tissue stem
cells or progenitor cells of more limited regenerative capacity
and differentiating plasticity as the cells that sustain the onco-
genic mutation. Two strategies have been used most commonly
to investigate this question. The first assesses the capacity of
isolated cells to produce cancers when an activating transgene
known in humans to be associated with a specific cancer type
is inserted. An example is the production of leukemia-initiating
cells when a leukemogenic MLL fusion gene is inserted into
either hematopoietic stem cells or myeloid progenitor cells of
a more limited differentiation spectrum (Cozzio et al., 2003).
This model suggests that cells that have lost stem cell character-
istics can regain that capacity when driven by an activated onco-
gene. The second uses cell-specific Cre expression to induce
tumorigenesis, and such mapping is being used more frequently
as cell-specific Cre alleles become available. Recent examples
of this strategy include the use of Cre driven by the Lgr5
promoter specifically in colonic crypt stem cells to adduce
evidence that these are the cells of origin of murine colon cancer
(Barker et al., 2007) as well as the use of other cell-specific
promoters to drive limited Cre expression (Barker et al., 2009;
Le et al., 2009; Schuller et al., 2008; Wang et al., 2009; YangSignificance
Basal cell carcinomas, the most common of human cancers, ar
cytes of the hair follicle, sebaceous glands, and interfollicular e
our ionizing radiation-treated Ptch1+/mice, both cell fate map
p53 demonstrate conclusively that the BCCs arise from the ha
p53 is deleted, BCCs can arise from the interfollicular epidermis
edly, p53 may inhibit susceptibility to BCC carcinogenesis in p
114 Cancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc.et al., 2008). These recent molecular approaches complement
older studies in which temporal separation of initiation and
promotion of two stage skin chemical carcinogenesis argues
that the cell of origin must be a stem cell since those are the
only cells expected to persist for such a long duration (Morris,
2000; Perez-Losada and Balmain, 2003). We have used the
second, Cre-Lox approach to investigate the identity of the cell
of origin of basal cell carcinomas (BCCs) in Ptch1+/ mice.
BCCs, the most common human cancer, are so named
because of their histologic resemblance to basal cells of the in-
terfollicular epidermis (IFE), the hair follicle, and the sebaceous
gland, i.e., the keratinocytes adjacent to the stroma. Several
lines of evidence suggest that BCCs not only histologically
resemble but also may arise from basal cells specifically of the
hair follicles. First, BCCs express cytokeratins that more closely
resemble those of follicular outer root sheath cells than those of
the basal layer of the IFE, the inner root sheath, or the hair shaft
(Donovan, 2009). Second, BCCs arise as the result of mutation-
driven aberrant activation of Hedgehog (HH) signaling, a pathway
whose activity in normal adult skin is limited essentially to folli-
cles (Dahmane et al., 1997; Oro et al., 1997). Third, after expo-
sure of the scalp to ionizing radiation, BCCs have occurred
concomitantly with trichoblastoma (Fazaa et al., 2007), a tumor
type more closely resembling the follicle. BCCs would appear
to be uniquely suited for studies of the cell of cancer origine so named because of their resemblance to basal keratino-
pidermis. However, the actual cell of origin is not known. In
ping and enhancement of BCC carcinogenesis by deletion of
ir follicle bulge stem cell. In mice in which basal keratinocyte
, likely due to enhanced expression of Smo. Thus, unexpect-
art by affecting expression of signaling components.
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Cell of Origin of Murine Basal Cell Carcinomabecause (1) activation of hedgehog signaling may be all, or at
least nearly all, that is required to transform a normal keratino-
cyte into a BCC cell and (2) keratinocyte stem cell populations
have been studied extensively and insightfully over some
decades (Blanpain and Fuchs, 2009).
However, despite the indirect evidence favoring a follicular
origin of BCCs, one recently published study found the murine
cell of origin of cutaneous HH-driven tumors to be the IFE and
not the follicle (Youssef et al., 2010). This study used cell-specific
Cre to activate expression of a ROSA26-driven transgenic
mutant Smoothened (Smo) whose signaling is not inhibited by
Patched 1 (Ptch1). By contrast, the current study was designed
to address this question in a different mouse model in which HH
signaling is activated by mutagenic insults of Ptch1+/ mice
rather than by transgenic mutant Smo.
RESULTS
Cell Fate Mapping of Hair Follicle Bulge Cells
and Their Descendents Using Yellow Fluorescent
Protein in Adult Ptch1+/– Mice
We assessed the cell of origin of BCCs in Ptch1+/ mice. Nor-
mally HH signaling is inhibited by Ptch1 protein’s blocking of
signaling by the downstream component Smo, and this inhibition
by Ptch1 is abrogated by its binding of the hedgehog ligand.
Ptch1 acts as a tumor suppressor gene; PTCH1+/ humans
(with the basal cell nevus [Gorlin] syndrome, OMIM 109400)
(Hahn et al., 1996; Johnson et al., 1996) and Ptch1+/ mice are
highly susceptible to developing BCCs after mutagenic insults
such as ionizing or ultraviolet radiation (Aszterbaum et al.,
1999; Mancuso et al., 2004). Of sporadic human BCCs, approx-
imately 90% have mutations in at least one copy of PTCH1while
approximately 10%of sporadic BCCs carry activating mutations
in SMO (Epstein, 2008). The most studied skin stem cell is
located in the outer root sheath of the follicle, in the bulge region
below the site of insertion of the arrector pili muscle (Blanpain
and Fuchs, 2009; Watt and Jensen, 2009). Bulge cells are char-
acterized by long-term self-renewal, slow cycling, and high
proliferative capacity. These cells are activated periodically to
enable cyclic regrowth of the hair follicle, and after wounding
they can at least temporarily contribute to IFE reconstitution
(Blanpain et al., 2004; Cotsarelis et al., 1990; Ito et al., 2005;
Morris et al., 2004; Morris and Potten, 1999; Taylor et al., 2000;
Tumbar et al., 2004). The most widely used hair follicle bulge
cell markers are keratin 15 (K15), CD34, and, during telogen,
Lgr5 (Cotsarelis et al., 1990; Jaks et al., 2008; Liu et al., 2003;
Morris et al., 2004; Trempus et al., 2003; Tumbar et al., 2004).
To determine whether these follicular bulge stem cells might
be the cell of origin of murine BCCs, we produced Ptch1+/
mice in which RU-486-regulated Cre is expressed under the
control of a bulge-specific promoter: K15-CrePR1 (Morris
et al., 2004). For fate mapping, we crossed these Ptch1+/
K15CrePR1 mice with ROSA26 reporter mice that express
enhanced yellow fluorescent protein (YFP) following Cre-medi-
ated excision of a loxP-flanked transcriptional stop sequence
(lsl) (Srinivas et al., 2001). We treated the resulting Ptch1+/
K15CrePR1 YFP lsl/lsl mice, designated ‘‘Y15,’’ with RU-486
for 3 days at age 7.5 weeks, an age when hair follicles are in tel-
ogen and K15 expression is restricted to the follicle bulge regionC(Morris et al., 2004) (Figure 1A). Thus, in these mice, K15-ex-
pressing bulge stem cells and their descendants express YFP.
For comparison, we activated Cre in Ptch1+/ mice in which
its expression is driven by the K14 promoter, i.e., Ptch1+/
K14-CreER2 YFP lsl/lsl (‘‘Y14’’) mice, by 3 days of treatment
with tamoxifen at age 7.5 weeks. The K14 promoter is transcrip-
tionally active in the basal cells of the follicle, the IFE, and the
sebaceous glands. To confirm the RU-486- or tamoxifen-depen-
dent tissue specific activation of YFP expression, we biopsied
skin of Y15 or Y14 mice 1 day after the last dose of RU-486 or
tamoxifen treatment and assessed the location of YFP expres-
sion. As shown in Figure 1, RU-486-treated Y15 mice expressed
YFP in the follicle bulge region, colocalizing with K15 expression
(Figures 1B and 1C). The IFE essentially lacked YFP expression.
By contrast, tamoxifen-treated Y14 mice expressed YFP in
epidermal basal cells, irrespective of K15 expression (Figures 1D
and 1E). We noted that not all K15-expressing bulge cells
expressed YFP in Y15 mice. By contrast tamoxifen-treated
Y14 mice had only occasional unlabeled follicles or IFE basal
cells. To compare the efficiency of YFP activation driven by the
two Cre alleles, we quantitated YFP labeling of K15-expressing
cells in skin biopsies of Y15 and Y14 mice (five mice per group).
In Y15 mice, approximately 56% (ranging from 36% to 69%) of
K15-expressing cells also expressed YFP. In Y14 mice, approx-
imately 83% (ranging from 62% to 94%) of K15-expressing cells
expressed YFP. This lack of 100% labeling efficiency is consis-
tent with findings of others (Liu et al., 2003; Srinivas et al.,
2001). The greater percentage of YFP-labeled K15-expressing
cells in the K14-CreER2 mice indicates a more efficient expres-
sion and/or activation of the CreER2/tamoxifen than of the
CrePR1/RU-486 system in K15-expressing follicular cells.
YFP-Expressing Microscopic and Macroscopic BCCs
Arise in Y15 and Y14 Mice
Oneday after the last dose of RU-486 or tamoxifen (age 8weeks),
when YFP-positive cells in Y15 mice remained confined to the
bulge, we treated the mice with 4Gy of ionizing radiation. At
age 9 months, grossly normal appearing dorsal skin of both
Y15 and Y14 mice contained YFP-positive and YFP-negative
microscopic BCCs (Figures 2A and 2B). The fraction of tumors
that were YFP-positive was consistent with the percentage of
the K15-expressing follicle cells that were YFP+ (49% versus
56% for Y15 and 77% versus 83% for Y14). Although tumors ap-
peared in random sections to be in close proximity to either the
follicle or to the IFE, careful examination of serial sections of skin
biopsies indicated that more than 90% of microscopic BCCs in
Y14 or Y15 mice had direct connections with a follicle in at least
one section (Figures 2C to 2F). The few remaining tumors may
indeed have arisen from IFE cells, or their apparent lack of
connection to the follicle may have been an artifact due, e.g.,
to missed sections. In addition, we found no significant differ-
ences in the tumor burden (tumor multiplicity and sizes of the
microscopic tumors) between YFP-expressing mice and non-
YFP-expressing control mice (Ptch1+/ YFP lsl/lsl littermates
lacking Cre), indicating that the expression of YFP did not affect
skin keratinocyte BCC tumorigenesis.
Starting at age 9 months, consistent with our past experience
with Ptch1+/ mice, some mice developed macroscopic BCCs.
We found strong YFP staining in tumor cells and no such stainingancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc. 115
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Figure 1. K15- or K14-Expressing Cells Are
Specifically Marked with YFP in Adult Y15
or Y14 Mice
One day after the last dose of RU-486 or tamox-
ifen, the skin of Y15 or Y14 mice were biopsied
and immunostained with anti-K15, anti-K14 or
anti-YFP antibodies. Color coding indicates anti-
body labeling. Scale bars = 50 mm.
(A) A selective image shows that K15-expressing
cells are restricted to the bulge region and the
K14-positive cells line the whole hair follicle
including the isthmus region, as well as the IFE.
(B) In Y15 mice, YFP was present in K15-express-
ing follicles but absent from IFE (dashed line).
(C) In Y15 mice, some K15-expressing follicles
failed to express YFP (arrows).
(D) In Y14 mice, YFP was present in both follicles
and in the IFE.
(E) In Y14 mice, occasional regions of IFE or
follicles (arrows) were free of YFP expression.
Cancer Cell
Cell of Origin of Murine Basal Cell Carcinomain stromal regions in both Y15 and Y14 mice (Figure 3A). Consis-
tent with our findings 1 day after Cre activation, YFP expression
in normal appearing skin surrounding BCCs in Y15 mice was
limited to follicles (Figure 3B) but was present in both the IFE
and follicles in Y14 mice. YFP-negative visible tumors, like YFP
negative microscopic BCCs at age 9 months, were present in
both Y15 and Y14 mice. These might have arisen from non-
K15 expressing cells and/or from K15-expressing cells in which
RU486-mediated Cre activation failed to delete the lsl sequence.
Because only a small number of macroscopic tumors devel-
oped, our study had insufficient statistical power to assess the
correlation between the percentage of visible YFP-expressing
tumors and the YFP-labeling efficiency of hair follicles.
Taken together, these cell fate mapping studies indicate
that K15-expressing cells are the predominant, and likely the
exclusive, cells of origin of BCCs in ionizing radiation-treated
Ptch1+/ mice.116 Cancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc.BCC Tumorigenesis in Ptch1+/–
p53–/– Mice
Ptch1+/p53/ mice develop early and
near uniformly fatal medulloblastomas
(Wetmore et al., 2001). Similarly, we
have observed dramatic acceleration of
BCC formation in Ptch1+/mice in which
p53 deletion is limited to K14-expressing
keratinocytes (G.Y.W., E.H.E., unpub-
lished data). Hence as a second indicator
of the cell of origin of BCCs, we com-
pared the enhancement of BCC carcino-
genesis when we deleted p53 in the
follicular bulge subset of basal keratino-
cytes with the enhancement when we
deleted p53 in all basal keratinocytes -
Ptch1+/ K15CrePR1 p53fl/fl (‘‘PF15’’)
and Ptch1+/ K14CreER2 p53fl/fl
(‘‘PF14’’) mice. Since p53 functions
primarily in a cell autonomous manner,
we expected that deletion of p53 inK15-expressing cells would also enhance BCC carcinogenesis
were K15-expressing cells indeed the BCC cell of origin.
We activated Cre endonuclease and treated with ionizing radi-
ation as in the Y14 and Y15 mouse studies, i.e., RU-486 or
tamoxifen injection at age 7.5 weeks for 3 days followed the
next day by ionizing radiation. Control Ptch1+/ p53fl/fl (lacking
a Cre transgene) mice generated either from PF15 or PF14
breedings had similar microscopic tumor burden, confirming
that mice of the two genotypes shared a similar baseline level
of tumor susceptibility.
Both PF15 and PF14 mice developed macroscopic BCCs
from age 5 to 8 months, an age significantly younger than the
age 9–13 months when p53 wild-type Y15 and Y14 mice devel-
oped visible BCCs (Kaplan-Meyer curve, p < 0.01, Figure 4A).
Despite the same tumor latency and tumor incidence (100%
macroscopic tumor-bearing mice in both PF15 and PF14 geno-
types), PF14 mice had considerably greater tumor multiplicity
A B
C D
FE
Figure 2. YFP-Expressing Microscopic
BCCs Arise from Y15 and Y14 Mice
(A and B) The skin biopsies of Y15 (A) and Y14 (B)
mice were immunostained with anti-YFP antibody
(brown) and counterstained with hematoxylin
(blue). Arrows denote the representative YFP-
positive microscopic BCCs. Scale bars = 50 mm.
(C to F) Representative images of serial sections of
a skin biopsy. A total of 15 serial sections of 5 mm
in thickness per section were stained with H & E
andexaminedforanyhair follicleconnectionofevery
singlemicroscopicBCConall serial sections. Selec-
tive images represent sections fromone sample that
show no connection to the follicle in (C) and (D) and
surrounds a follicle in (E) and (F). Arrows indicate
microscopic BCC. Scale bars = 50 mm.
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particular at age 7 and 8 months (Fold = 5, p < 0.01) (Figure 4B).
Consistent with the differing numbers of visible BCCs, we
found 70% more microscopic BCCs at age 5 months in PF14
mice than in PF15 mice (p < 0.01). Interestingly, the fraction of
microscopic BCCs that were free of follicle connection, i.e.,
IFE-microscopic BCCs, on serial sections was significantly
increased in PF14 mice over that in PF15 (TTEST, p < 0.05) or
(p53-wild-type) Y15 or Y14 mice (p < 0.01, Figure 5). The signif-
icant enhancement of IFE-microscopic BCCs in PF14 mice
compared to PF15, Y15, and Y14 mice suggests that loss of
p53 sensitizes IFE cells to BCC tumorigenesis.
Two Different BCC Subtypes
Next, we classified the macroscopic BCCs in the four groups of
mice into two histopathologic subtypes (Figure 6). Type I BCCs
had branching and radiating tumor cells, more reminiscent of
follicular differentiation, and some cells contained smooth
muscle actin (SMA). Type II BCCs had basaloid cells arrayed in
nests not resembling follicular differentiation and lacked tumor
cell SMA staining. Additionally, type I tumors hadmore extensiveCancer Cell 19, 114–124,stroma than did type II tumors. Tumors in
PF15, Y15, and Y14 mice were 95%–
100% of type I (Figure 5). However, in
PF14 mice, only 80% of the tumors
were of type I; the remaining 20% were
of type II. Thus, PF14 mice have both
more microscopic BCCs lacking connec-
tion to the follicle and more visible BCCs
of type II histology. The correlation
(nonparametric correlation, Spearman,
p = 0.04) suggests that murine BCCs
arising from the IFE are more likely of
type II histology, consistent with the
finding of Mancuso and colleagues that
SMA-expressing BCCs arise from folli-
cles (Mancuso et al., 2006).
SMO Is Necessary for BCC
Tumorigenesis
In general, mouse models in which the
HH pathway is activated downstream ofPtch1, e.g., transgenic expression of SmoM2 and Gli2, produce
HH-driven tumors predominantly on the ears and tail. By
contrast, no visible BCCs and only occasional basaloid hyper-
proliferation and (at ages later than on dorsal skin) microscopic
BCCs develop at these sites in our Ptch1+/mice. To investigate
one possible basis for the differing sites of BCC development in
the different models, we used immunostaining to analyze tissue
distribution of Smo protein expression. The great majority of
follicles of the ear and tail of Ptch1+/mice fail to express immu-
nohistochemically detectable Smo protein (Figures 7A–7C). An
exception to this is the elongated anagen follicle which, like
follicles of similar morphology in the dorsal skin, does express
Smo. But we found such follicles only rarely in tail and not at all
in ear tissue. In dorsal skin of Ptch1+/, p53 wild-type (i.e., Y14
and Y15, Figures 7D and 7E) mice, Smo staining occurs in hair
follicles (anagen) and in some, albeit not all, microscopic tumors.
Dorsal skin IFE expresses essentially no immunohistochemically
detectable Smo protein. Upon K14-Cre mediated deletion of
p53, we found increased Smo expression not only in the follicles
but also, crucially, in the IFE (Figures 7F and 7G). These data
suggest that Ptch1+/, p53 wild-type mice fail to developJanuary 18, 2011 ª2011 Elsevier Inc. 117
AB
Figure 3. YFP-ExpressingMacroscopic BCC Tumors Arise fromY15
Mice
(A) A representative macroscopic BCC generated from Y15 mice was stained
with anti-YFP antibody (brown) and counterstained with hematoxylin (blue).
Scale bar = 50 mm.
(B) Examination of the normal-looking skin surrounding the tumor confirmed
that follicles expressed YFP while the IFE was free of YFP expression.
Scale bar = 50 mm.
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B
PF15 PF14 Fold p value
26.33 ± 10.17 47.86 ± 6.16.30 1.69 0.01
0.25 ± 0.46 0.63 ± 0.92 2.00 0.48
0.63 ± 0.74 2.88 ± 2.64 3.97 0.06
1.86 ± 1.57 7.86 ± 3.60 4.80 0.01
2.50 ± 1.05 12.20 ± 2.17 4.90 0.01
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Microscopic BCCs
Macroscopic BCCs
Figure 4. Deletion of p53 Specifically in Either K15- or K14-Express-
ing Cells Accelerates BCC Tumorigenesis in Ptch1+/– Mice
(A) Tumor latency of macroscopic BCC development in PF15, PF14, and
p53WT (combined data of Y15 and Y14) were analyzed with Kaplan-Meier
curve (p < 0.01).
(B) The tumormultiplicity of microscopic andmacroscopic BCCwas assessed
at mouse age 5–8 months. Fold differences between PF14 and PF15 mice and
p values are shown. Data are shown as means ± SD (n = 8).
0% 10% 20% 30%
Y15
Y14
PF15
PF14
IFE microscopic BCC
Type II macroscopic BCC
*
**
**
Figure 5. The Ratio of IFE Microscopic BCCs Is Increased in PF14
Mice and Appears Associated with Type I Macroscopic BCCs
The fraction of microscopic BCCs that were free of follicle connection, i.e., the
IFE microscopic BCCs, is plotted with the percentage of type II macroscopic
tumors. Data are normalized against total number of tumors and shown as
mean ± SD (n = 4) with p values < 0.05 (*) or < 0.01 (**).
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Cell of Origin of Murine Basal Cell CarcinomaBCCs on the ears, tails, and dorsal IFE because they do not
express significant amounts of Smo protein at these sites, and
therefore loss of Ptch1 is irrelevant to HH activation. Corre-
spondingly, increased expression of Smo in the IFE in mice in
which p53 has been deleted from the IFE correlates with devel-
opment of microscopic BCCs at these sites.
An additional discrepancy between SmoM2 mice (Yousseff
et al., 2010) and our Ptch1+/ mice is the failure of the former
to generate tumors in the follicle, despite follicular expression
of the transgene (Yousseff et al., 2010) and the arising of tumors
exclusively from the follicle in the latter. One possible explana-
tion for this difference is that Ptch1 protein might have functions
other than the inhibition of HH signaling. One described such
non-HH function of Ptch1 is the tethering of cyclin B1 in the
cytoplasm and consequent prevention of its normal function in
the nucleus (Barnes et al., 2001). Therefore, we compared
the location of cyclin B1 in tumors arising in the two models.
As predicted, cyclin B1 is predominantly cytoplasmic in118 Cancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc.HH-driven tumors of SmoM2 mice whereas in marked contrast
it is clearly nuclear inBCCsof IR-treatedPtch1+/mice (Figure 8).
This difference suggests that BCCs arising from the follicle may
require nuclear cyclin B1, whereas tumors arising from the IFE
may not require cyclin B1 nuclear action.
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Figure 6. Two Distinct Histopathologic
Subtypes of Macroscopic BCCs
(A and B) Representative images of type I histo-
logic feature show branching, radiating tumor
structure (arrow) and patchy expression of SMA
(brown) in tumor cells. Scale bar = 50 mm.
(C and D) Representative images of type II histo-
logic feature show nests of tumor cells and
positive SMA staining limited to the stroma.
Scale bar = 50 mm.
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These studies generate several conclusions. The first is that
IR-induced BCCs in Ptch1+/ mice arise predominantly, and
likely exclusively, from K15 expressing hair follicle bulge stem
cells. Thus, activation of YFP expression in K15-expressing adult
mouse follicle bulge stem cells produces YFP-positive micro-
scopic and macroscopic BCCs, and deletion of p53 limited to
these same cells dramatically enhances BCC tumorigenesis.
We believe that the most parsimonious explanation for the
presence of non-YFP expressing BCCs is the variable, less
than 100% efficiency of Cre-mediated activation of YFP expres-
sion because in the Y14 and Y15 mice the fraction of BCCs that
are YFP+ is similar to the fraction of K15+ follicular cells that are
YFP+ and because we find a direct physical connection between
follicle and microscopic BCCs in nearly all IR-treated wild-type
p53, Ptch1+/ mice. However, we cannot exclude completely
the possibility that a small fraction of YFP nonexpressing
BCCs in these mice might have arisen from cells of the IFE. On
the other hand, we and others (Liu et al., 2003) observe occa-
sional, randomly distributed K15-expressing cells in the adult
IFE, suggesting the possibility that some YFP-positive BCCs
could originate from these K15-expressing IFE cells. Since there
is no marker available for the specific targeting of keratinocytes
that express K14 but not K15, it is not possible to address this
question directly.
By contrast, our data indicate that the higher numbers of BCCs
in mice in which p53 is deleted not only from the follicular bulge
but also from the IFE are due at least in part to a contribution byCancer Cell 19, 114–124non-K15-expressing cells to tumor
formation, since in PF14 mice we find
significant numbers of microscopic
BCCs with no detectable physical con-
nection to the follicle. In addition, some
of the visible BCCs that these PF14
mice develop have a histologic pattern
that differs from the pattern of BCCs
arising from the follicles. Our correlation
of the tumor phenotype of SMA expres-
sion with follicular origin is highly con-
gruent with data obtained by Saran’s
group using a different Ptch1+/ model
(Mancuso et al., 2006). As they noted,
several authors have identified human
BCCs expressing SMA but contrary to
expectations the degree of aggressive-
ness of human BCCs has been reportedmost recently to correlate with SMA expression in the stroma,
not in the tumor cells (Adegboyega et al., 2010).
Second, our results highlight phenotypic differences between
HH-driven cutaneous tumorigenesis in Ptch1+/ mice versus in
other murine models. One such difference is the body location
of tumor formation. Thus, in models in which tumorigenesis is
driven by abnormal alleles of downstream HH signaling genes,
activating mutations of Smo, heterozygosity for SuFu (Svard
et al., 2006), or overexpressed Gli2 (Hutchin et al., 2005) (albeit
not overexpressed Gli1; Nilsson et al., 2000) macroscopic
tumors that arise are located predominantly on the ears, tails,
and paws, whereas we have never seen a visible BCCs at these
sites in a decade of studies of Ptch1+/ mice. Our finding that
Smo is not expressed in the skin at these sites offers an attractive
explanation for this discrepancy. In so far as the function of Ptch1
is to inhibit Smo signaling, its loss in cells not expressing Smo
should be of little consequence—activation of HH signaling by
loss of Ptch1 function by ligand-binding (Walter et al., 2010) or
by inactivating mutation requires expression of downstream
components of the signaling machinery. Similarly, we believe
the discrepancy between our findings of a follicular origin of
BCCs and Yousseff et al.’s finding of an IFE origin of HH-driven
tumors arises at least in part because they used a mutant Smo
allele driven by a ROSA-26 promoter, thus bypassing low Smo
expression in the IFE of p53wild-typemice. Hence, the induction
of Smo IFE expression correlates with the lack or presence of
BCC tumorigenesis of this region.
There is an additional discrepancy between conclusions
reached with the two models; mice with activated Smo, January 18, 2011 ª2011 Elsevier Inc. 119
SMO
PF14
G
B Ear C Tail
A
Dorsal skin
SMO
Y15 or Y14
E
SMO/DAPI
D F
SMO/DAPI
Figure 7. Differential Expression of Smo
(A–C) Representative images of immunostaining
with anti-Smo antibody (brown) and counter-
stained with hematoxylin (blue) show absence of
staining in ear or tail and positive staining in dorsal
skin follicles.
(D and E) The skin biopsy of Y14 or Y15mouse that
is immunostained with anti-Smo antibody (green)
shows that Smo is detected in follicles and some
microscopic BCCs (arrows) but not in IFE (dashed
line). (E) No DAPI counter staining. Scale bars =
50 mm.
(F and G) The skin biopsy of PF14 mouse that is
immunostained with anti-Smo antibody (green)
shows that Smo is detected in follicles and some
microscopic BCCs (arrows) as well as in IFE
(dashed line). (G) No DAPI counter staining.
Scale bars = 50 mm.
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et al., 2010), suggesting that follicular bulge cells are resistant to
transformation by hedgehog signaling (Ridky and Khavari, 2010).
One potential explanation for this discrepancy is that tumori-
genic transformation of K15+ cells might require loss of functions
of Ptch1 other than its inhibition of HH signaling. Indeed Ptch1
protein has been described as inhibiting cell cycle progression
via tethering cyclin B1 in the cytoplasm and preventing its access
to the nucleus (Barnes et al., 2001), and our finding of differential
localization of cyclin B1 in the two models is consistent with that
hypothesis. Other currently cryptic non-HH functions of Ptch1120 Cancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc.may exist. A relative requirement for
ablation of non-HH inhibitory function(s)
of Ptch1 might be one reason that the
great majority of human BCCs carry
mutations of Ptch1 rather than of other
components of the HH pathway despite
the ability of engineered mutants of
downstream components to drive murine
BCC tumorigenesis.
Third, our finding that deletion of p53
increases expression of keratinocyte
Smo is of particular interest in that human
BCCs, which frequently carry mutant p53
(Ling et al., 2001; Reifenberger et al.,
2005), typically arise on chronically
sun damaged skin containing clones of
epidermal keratinocytes expressing
mutant p53 (Backvall et al., 2004; Ziegler
et al., 1994). Thus such p53 mutations
may render human IFE cells competent
for the development of BCCs, in part by
enhancing expression of SMO protein.
This suggests that the p53 mutations in
human BCCs are not simply passengers
due to the arising of BCCs on skin con-
taining mutant p53 but rather are direct
contributors to BCC carcinogenesis, in
part by enhancing expression of SMO
and thereby sensitizing epidermal kerati-nocytes to the oncogenic effects of PTCH1 loss. Furthermore,
they would provide an explanation for the seeming conundrum
that some mutations in PTCH1 and p53 in human BCCs are of
the UVB signature type (Aszterbaum et al., 1998; Chidambaram
et al., 1996; Gailani et al., 1996a, 1996b; Lench et al., 1997; Rady
et al., 1992; Unden et al., 1996; Wicking et al., 1997; Wolter et al.,
1997) even though human hair follicle bulge stem cells may
be too deep in the dermis to be reached by mutagenic UVB.
Of interest, p53 loss can enhance normal neural stem cell
self-renewal (Meletis et al., 2006), rescue epidermal stem cell
function in telomerase-deficient mice (Flores and Blasco,
A: Smo/M2
B: Ptch1+/-
Figure 8. Differential Localization of Cyclin B1 in BCCs Developed
from Ptch1+/– or Smo/M2 Mouse Model
Representative immunostained images with anti-cyclin B1 antibody (red).
Insets are images in higher magnification. Scale bars = 50 mm.
(A) Cutaneous tumor of Smo/M2 mouse shows cells with generally weak and
cytoplasmic cyclin B1 (arrows).
(B) BCC of Ptch1+/ mouse has cells with strong nuclear cyclin B1.
Cancer Cell
Cell of Origin of Murine Basal Cell Carcinoma2009), and enhance reprogramming of somatic cells, in partic-
ular human keratinocytes, to a more stem-like state (Kawamura
et al., 2009), and hedgehog signaling may be important for
maintenance of normal tissue and cancer stem cells (Agarwal
and Matsui, 2010; Scales and de Sauvage, 2009; Zhao et al.,
2009). Thus increased expression of Smo may be one mecha-
nism by which p53 loss contributes to stemness. Furthermore,
there is a parallel between newer views of p53’s role in influ-
encing cell size and the finding that Ptch1+/ humans and mice
are larger than their Ptch1 wild-type siblings (Goodrich et al.,
1997; Milenkovic et al., 1999); perhaps inhibition of HH signaling
by p53 via Smo downregulation might be another mechanism
underlying this inhibition of cell growth by p53 (Gottlieb and
Vousden, 2010; Vousden and Ryan, 2009).
The possibility that stem cells of the follicle are the cells of
origin of cutaneous cancers is one that has been considered
since, and even before, the initial localization of such cells to
the bulge (Cotsarelis et al., 1990). The current view is that these
cells can serve as the reservoir that regenerates the active, hair-Cproducing lower portion of the follicle that functions for a limited
time (anagen) before entering regressing (catagen) and then
resting (telogen) phases (Blanpain and Fuchs, 2009). These cells
also can repopulate the IFE, not under normal homeostasis but
only following injury and likely only transiently (Claudinot et al.,
2005; Ghazizadeh and Taichman, 2001; Ito et al., 2005; Langton
et al., 2008; Levy et al., 2005). Recently, the hair germ that lies at
the lower end of the bulge has been identified as the proximate
source of the lower follicle and can be identified specifically by
expression of Lgr5, which also is a marker of stem cells in the
colon (Barker et al., 2007; Jaks et al., 2008; Sato et al., 2009).
In addition, Lgr6-expressing cells located above the bulge
appear to be one postnatal stem cell population of the IFE
and sebaceous glands (Snippert et al., 2010). These cells
express K14 but not K15 (Snippert et al., 2010; Figure 1A), and
hence despite their postulated role as the most primitive of
epidermal stem cells, are not the cell of origin of BCCs in p53
wild-type mice. Thus, it is possible that susceptibility to transfor-
mation to BCCs by HH activation requires some commitment to
a more differerentiated fate. Of note, HH-induced murine medul-
loblastomas occur only when precursors have committed to
granule cell lineage, irrespective of whether or not the mutation
is present in earlier stage stem cells (Schuller et al., 2008; Yang
et al., 2008).
In summary, based both on fate mapping and on the impact
of p53 deficiency on BCC tumorigenesis, we conclude that
K15-expressing cells are the predominant cells of origin of
Ptch1+/ murine BCCs, irrespective of p53 status. The loss of
p53 significantly enhances the tumor-initiating capacity not
only of follicular cells but also of non-K15 expressing cells,
such as those of the IFE. Furthermore, comparison of HH-driven
carcinogenesis in Ptch1+/mice versus in Smo-Mut mice points
to the essential role of expression of Smo in BCC carcinogenesis
and suggests a functional role for the cytoplasmic tethering of
cyclin B1 by Ptch1 protein.EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice and IR-Induced BCC Tumorigenesis
Mice carrying engineered alleles were kindly provided by A. Berns (p53fl/fl)
(Jonkers et al., 2001), P. Chambon, (K14-Cre-ER2) (Indra et al., 2000),
F. Costantini (ROSA26 YFP lsl) (Srinivas et al., 2001), and G. Cotsarelis
(K15-Cre-PR1)(Morris et al., 2004). For lineage analysis, K15-CrePR1 and
K14-CreER2 mice were crossed with ROSA26 floxed-stop YFP and Ptch1+/
mice (Aszterbaum et al., 1999) to generate Ptch1+/ K15-Cre-PR1 YFP lsl/lsl
(Y15 mice) or Ptch1+/ K14-Cre-ER2 YFP lsl/lsl (Y14 mice). For p53 deletion
studies, K15-CrePR1 and K14-CreER2 mice were crossed with p53fl/fl and
Ptch1+/ mice to generate Ptch1+/ K15-Cre-PR1 p53fl/fl (PF15 mice) or
Ptch1+/ K14-Cre-ER2 p53fl/fl (PF14 mice). To minimize any genetic back-
ground differences in susceptibility to BCC formation, we intercrossed PF15
and PF14 mice to produce offspring of similar backgrounds. All mice were
genotyped by PCR amplification of genomic DNA extracted from tail snips
using DirectPCR Lysis Reagent (Tail) following the manufacturer’s instruction
(Viagen Biotech, Los Angeles, CA). The primer sequences and PCR conditions
were described previously (Indra et al., 2000; Jonkers et al., 2001; Morris et al.,
2004; Srinivas et al., 2001). Mice were housed under standard conditions
(fluorescent lighting 12 hr per day, room temperature 23C–25C, and relative
humidity 45%–55%). Animal care and use were in compliance with the proto-
cols approved by the Institutional Animal Care and Use Committee (IACUC) of
Children’s Hospital Oakland Research Institute (CHORI).
To activate Cre-mediated recombinase activity, mice were injected intraper-
itoneally with 750 mg RU486 (Y15 and PF15) or 100 mg tamoxifen (Y14 andancer Cell 19, 114–124, January 18, 2011 ª2011 Elsevier Inc. 121
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Cell of Origin of Murine Basal Cell CarcinomaPF14, Sigma-Aldrich, St Louis, MO) daily at age 7.5 weeks for 3 consecutive
days. On the day following the last dose of treatment (i.e., age 8 weeks),
mice were subjected to IR at 4 Gy, 160 kV using an X-ray source (RadSource
RS2000 irradiator). The few Ptch1+/ K15-CrePR1 YFP lsl/lsl mice with signif-
icant numbers of YFP+ IFE cells in the 9 month biopsies were removed from
further analyses.
Skin Sampling and b-Galactosidase Staining
Standard mouse dorsal skin biopsy and b-galactosidase staining were per-
formed as described previously (Aszterbaum et al., 1999) except that a 1 3
1.5 cm rectangular area of skin was excised and divided into five slivers of
1 cm in width. After fixation with 2% formaldehyde (Fisher Scientific) 0.2%
glutaraldehyde mixture (Sigma), tissues were stained with a b-Gal Staining
Set according to the manufacturer’s instruction (Roche Diagnostics, Penz-
berg, Germany) followed by standard paraffin embedding, sectioning, and
hemotoxylin and eosin (H&E) stain. The stained slideswere scanned into digital
images by Aperio (Vista, CA), which were used to examine microscopic tumor
multiplicity using Aperio ImageScope software (v9.1.19.1569).
Immunostaining
Paraffin sections were deparaffinized and rehydrated. For immunohistochem-
istry, rehydrated samples were subjected to antigen retrieval with rodent de-
cloaker (Biocare Medical, Concord, CA) for 10 min at 95C –100C, followed
by incubation with rodent block M (Biocare Medical) for 15 min, primary
antibody for 1 hr, and secondary antibody, rabbit on rodent HRP-polymer or
MM HRP-polymer for 20 min (Biocare Medical). Signal was developed using
liquid DAB+ substrate (Dako, Carpinteria, CA) for 2-10 min and counterstained
with Cat hematoxylin (BiocareMedical) orMethyl green (Trevigen). The primary
antibodies were rabbit anti-YFP (1: 3000, Abcam, Cambridge, MA), rabbit
anti-Smo (1:200, Abcam), or mouse anti-SMA (1: 500, Sigma). For immunoflu-
orescent staining, antigen retrieved slides were blocked with 2%FBS followed
by incubation with primary antibodies: rabbit anti-YFP (1:100), anti-Smo
(1:100, LS-A2668, MBL, Woburn, MA) or mouse anti-cyclin B1 (1: 200, Invitro-
gen, Camerillo, CA) overnight at 4C. The secondary antibody conjugated with
Alexa Fluor 488 or 555 (1:1000, Molecular Probes, Eugene, OR) was used
together with DAPI (1:5000, Molecular Probes) to detect primary antibodies
followed by mounting with ProLong Gold Antifade Reagents (Molecular
Probes). All images were acquired using Nikon Eclipse E600 microscopy
and processed with imaging software IPLab (Scanalytics).
Statistical Analysis
All values are shown as mean ± standard deviation (SD). Nonparametric t test
(Mann-Whitney test), nonparametric correlation (Spearman), and Kaplan
Meier survival curve were performed to determine the statistical significance
(GraphPad Prism 4.0).
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